SymBio in 2 minutes
Unchanging philosophy of "Symbiosis"
Based on the philosophy of to co-create and to co-exist, we are working hard to develop groundbreaking new drugs.
Taking on Underserved Therapeutic Areas
We are currently developing brincidofovir, focusing our management resources on the treatment of post-transplant viral infections, blood cancers, solid cancers, and neurodegenerative diseases.
Outstanding new drug development and commercialization capabilities
The anti-cancer drug TREAKISYM, introduced in 2005, achieved early approval in just five years and has become the standard treatment for malignant lymphoma in Japan.
Leveraging our speedy new drug development and commercialization capabilities through our unique business model, we are working on the global development of "brincidofovir."
Breakthrough new drug candidate "brincidofovir"
brincidofovir an injectable antiviral drug introduced in 2019, has the unique property of being highly effective against many types of viruses. These properties have attracted the attention of many research institutions, and we are conducting collaborative research with academic and research institutions around the world. Furthermore, due to the antitumor effects discovered during the research process, it is expected that it may become a cancer treatment.
| Joint research destination | Research disease |
|---|---|
| Penn State College of Medicine | BK virus infection after kidney transplantation |
| National Institute of Infectious Diseases and Allergy (NIAID) | Post-transplant lymphoproliferative disorder (PTLD) |
| University of California, San Francisco | Glioblastoma (GBM) |
| National Cancer Centre Singapore (NCCS) | NK/T cell lymphoma, peripheral T cell lymphoma (PTCL) |
| National Institute of Neurological Disorders and Stroke (NINDS) | Multiple sclerosis (MS) |
| Tufts University | Alzheimer's disease (AD) |
brincidofovir is being developed in parallel
As it is expected to be effective against many types of viruses, development is currently underway in parallel. The treatment of pediatric adenovirus infections after hematopoietic stem cell transplantation has received fast track designation from the US FDA, and Phase III clinical trials are scheduled to begin in 2025.
Additionally, a Phase IIa clinical trial is underway for post-transplant cytomegalovirus infection.
Furthermore, an international Phase Ib clinical trial is underway for NK/T-cell lymphoma.
Aiming to become a global specialty pharmaceutical company
brincidofovir is currently undergoing research and development with research institutions around the world for seven diseases in three areas, and we aim to maximize business value by producing research results.
As a result, we aim to achieve a 50:50 ratio of domestic and international sales by 2030, "50-50 in 2030," and become a truly global specialty pharmaceutical company.